期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 109, 期 5, 页码 1232-1243出版社
WILEY
DOI: 10.1002/cpt.2074
关键词
-
资金
- US Food and Drug Administration
- Molecular Health, GmbH
The study enhanced a model to predict adverse events on drug labels at approval, using more drugs, features, and a new algorithm. Evaluating comparator drugs with similar target activities helped assess the risk of adverse events for the drug of interest.
We improved a previous pharmacological target adverse-event (TAE) profile model to predict adverse events (AEs) on US Food and Drug Administration (FDA) drug labels at the time of approval. The new model uses more drugs and features for learning as well as a new algorithm. Comparator drugs sharing similar target activities to a drug of interest were evaluated by aggregating AEs from the FDA Adverse Event Reporting System (FAERS), FDA drug labels, and medical literature. An ensemble machine learning model was used to evaluate FAERS case count, disproportionality scores, percent of comparator drug labels with a specific AE, and percent of comparator drugs with the reports of the event in the literature. Overall classifier performance was F1 of 0.71, area under the precision-recall curve of 0.78, and area under the receiver operating characteristic curve of 0.87. TAE analysis continues to show promise as a method to predict adverse events at the time of approval.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据